Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

F A Hayes

Showing results (91-100 of 93) with videos related to

Pageof 10
Sort By:
You have reached the last page of results.This site can display upto 93 results.
Cancer Chemotherapy and Pharmacology|January 1, 1989
Ifosfamide in pediatric malignant solid tumorsC B Pratt, E C Douglass, E L Etcubanas, et al.
American Journal of Surgery|September 1, 1996
Granulocyte-macrophage colony-stimulating factor as infection prophylaxis in high-risk oncologic surgeryN J Meropol, N J Petrelli, B J Lipman, et al.
American Journal of Hematology|June 28, 2001
Phase II study of combination human recombinant GM-CSF with intermediate-dose cytarabine and mitoxantrone chemotherapy in patients with high-risk myelodysplastic syndromes (RAEB, RAEBT, and CMML): an Eastern Cooperative Oncology Group StudyJ M Bennett, M S Young, J L Liesveld, et al.
Pageof 10

Showing results (91-100 of 93) with videos related to

Sort By:
Pageof 10
You have reached the last page of results.This site can display upto 93 results.
Cancer Chemotherapy and Pharmacology|January 1, 1989
Ifosfamide in pediatric malignant solid tumorsC B Pratt, E C Douglass, E L Etcubanas, et al.
American Journal of Surgery|September 1, 1996
Granulocyte-macrophage colony-stimulating factor as infection prophylaxis in high-risk oncologic surgeryN J Meropol, N J Petrelli, B J Lipman, et al.
American Journal of Hematology|June 28, 2001
Phase II study of combination human recombinant GM-CSF with intermediate-dose cytarabine and mitoxantrone chemotherapy in patients with high-risk myelodysplastic syndromes (RAEB, RAEBT, and CMML): an Eastern Cooperative Oncology Group StudyJ M Bennett, M S Young, J L Liesveld, et al.
Pageof 10